BIOARCTIC NEUROSCIENCE AB has a total of 78 patent applications. It decreased the IP activity by 50.0%. Its first patent ever was published in 2001. It filed its patents most often in United States, Australia and Canada. Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are TARGETED MOLECULAR DIAGNOSTICS, MASSACHUSETTS HEALTH RES and BOUGUELERET LYDIE.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 14 | |
#2 | Australia | 10 | |
#3 | Canada | 9 | |
#4 | EPO (European Patent Office) | 8 | |
#5 | WIPO (World Intellectual Property Organization) | 8 | |
#6 | China | 7 | |
#7 | Brazil | 2 | |
#8 | Hungary | 2 | |
#9 | Republic of Korea | 2 | |
#10 | Mexico | 2 | |
#11 | Sweden | 2 | |
#12 | South Africa | 2 | |
#13 | Argentina | 1 | |
#14 | Hong Kong | 1 | |
#15 | Jordan | 1 | |
#16 | Japan | 1 | |
#17 | Norway | 1 | |
#18 | New Zealand | 1 | |
#19 | Serbia | 1 | |
#20 | Russian Federation | 1 | |
#21 | Singapore | 1 | |
#22 | Taiwan | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement | |
#4 | Medical technology | |
#5 | Agriculture | |
#6 | Machines |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Therapeutic chemical compounds | |
#3 | Analysing materials | |
#4 | Medical preparations | |
#5 | Diagnosis and surgery | |
#6 | Object sterilising | |
#7 | Implantable devices | |
#8 | Animal care | |
#9 | Microorganisms | |
#10 | Unspecified technologies |
# | Name | Total Patents |
---|---|---|
#1 | Lannfelt Lars | 55 |
#2 | Sehlin Dag | 15 |
#3 | Gellerfors Par | 14 |
#4 | Gellerfors Paer | 14 |
#5 | Englund Hillevi | 14 |
#6 | Ekholm Pettersson Frida | 13 |
#7 | Ekberg Monica | 11 |
#8 | Screpanti Sundquist Valentina | 11 |
#9 | Kasrayan Alex | 11 |
#10 | Holmquist Mats | 11 |
Publication | Filing date | Title |
---|---|---|
AR101130A1 | ANTIBODIES OF UNION TO PROTOFIBRILLES Ab IMPROVED | |
CN104093367A | Spinal cord devices and methods for promoting axonal regeneration | |
CN106397588A | Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies | |
CA2765602A1 | N-terminal truncated protofibrils/oligomers for use in therapeutic and diagnostic methods for alzheimer's disease and related disorders | |
CA2630344A1 | Improved protofibril selective antibodies and the use thereof | |
AU2007200047A1 | Prevention and treatment of Alzheimer's disease | |
AU2005254928A1 | Antibodies specific for soluble amyloid beta peptide protofibrils and uses thereof | |
EP1729569A1 | Transgenic model for alzheimer's disease | |
EP1563066A2 | Methods for the identification of agents that modulate the structure and processing of beta-amyloid precursor protein | |
EP2082749A2 | Prevention and treatment of Alzheimer's disease |